Naima Benannoune

PCIF1 loss licenses antitumour immunity via cholesterol biosynthesis

Kaixiu Li, Tianjian Lu, Zheyu Ding, Mengyao Wang et autres

Abstract Cholesterol biosynthesis is classically viewed as a tumour supportive metabolic programme, yet cholesterol-associated metabolic states can paradoxically coincide with improved responses to immune checkpoint blockade (ICB) 1 , highlighting an unresolved context-dependent relationship between cholesterol homeostasis and antitumour immunity. Here we …

cn, fr (code pays fourni par la source)

Clinical validation of an AI-based prognostic assay for stage I-II cutaneous melanoma.

Christina Kanaan, Céline Bossard, Séverine Roy, Naima Benannoune et autres

9578 Background: In early-stage cutaneous melanoma (CM), AJCC staging demonstrates limited ability to identify patients at elevated recurrence risk who may benefit from adjuvant therapy or intensified surveillance. We evaluated DiaSurv, an AI-based prognostic assay analyzing standard H&E whole-slide images (WSI) to …

fr (code pays fourni par la source)

Early ctDNA dynamics assessed by a personalized whole-genome sequencing-based assay as a predictor of outcomes with immune checkpoint blockade in advanced melanoma.

Mora Guardamagna, Noémie Simon-Tillaux, Séverine Roy, Émilie Routier et autres

3053 Background: Circulating tumor DNA (ctDNA) is an emerging biomarker for assessing treatment outcomes and monitoring disease recurrence in melanoma. However, evidence supporting its clinical utility at very early on-treatment timepoints remains limited. We evaluated whether ctDNA dynamics relative to a single …

fr, us (code pays fourni par la source)

Persistance tumorale dans le mélanome : comment les cellules persistantes neutralisent le système immunitaire

L. Soumoy, H. Chen, Sara Faouzi, Shensi Shen et autres

Isoenzymes de la LDH et pronostic du mélanome : nouvelle approche pour les stades IV

Laura Soumoy, V. Quidville, Caroline Pradon, Ludovic Lacroix et autres

Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study

Mario Mandalà, Teresa Amaral, Piotr Rutkowski, Maria Chiara Sergi et autres

BACKGROUND: Ipilimumab plus nivolumab (COMBO) is the standard treatment in patients with asymptomatic melanoma brain metastases (MBM). We report a retrospective study aiming to assess the outcome of patients with MBM treated with COMBO with or without sequential/concomitant stereotactic radiotherapy (SRT). METHODS: …

it, de, pl, fr, gb, es, be, au (code pays fourni par la source)

Use of artificial intelligence to identify high risk profiles in early stage melanoma patients from pathology slides.

Christina Kanaan, Céline Bossard, Séverine Le Roy, Naima Benannoune et autres

9579 Background: To refine prognostication in primary cutaneous melanoma (CM) and optimize adjuvant treatment decisions, we evaluate SmartProg-MEL (SPM), an AI-based histology-driven algorithm developed by DiaDeep and applied to H&E-stained whole-slide images (WSI) at the time of diagnosis. SPM provides a risk …

fr (code pays fourni par la source)

Abstract 4444: Targeting eIF4F-mediated translation to reduce T cell exhaustion and enhance PD-1 blockade efficacy in melanoma

Samad Muhammadnejad, Monireh Kazemimanesh, Naima Benannoune, Sandrine Agoussi et autres

Abstract Background: The eukaryotic initiation factor 4F (eIF4F) complex is essential for the selective translational control of protein expression enabling cells to rapidly adapt to diverse stimuli. We previously identified an eIF4F/STAT1/PDL1 axis in melanoma cells. The effectiveness of cancer immunotherapy, particularly …

fr (code pays fourni par la source)

3MO LDH isoforms shape the immune microenvironment and impact treatment response and survival in metastatic melanoma

Laura Soumoy, Virginie Quidville, C. Sarre-Pradon, Ludovic Lacroix et autres

TC) and using the combined positive score (CPS).TILs or PD-L1 increase was defined by an absolute change of 1 %.Results: Baseline TILs > 1% were observed in 51.5% of pts and this proportion decreased in the 3 arms at W6. Baseline PD-L1 …

fr (code pays fourni par la source)

Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy

Rachel Woodford, Janet McKeown, Lotte L Hoeijmakers, Johanna; https://orcid.org/0000-0003-3962-7575 Mangana et autres

Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy

Rachel Woodford, Janet McKeown, Lotte Hoeijmakers, Johanna Mangana et autres

au, nl, ch, us, fr, es, pl, be, it (code pays fourni par la source)

Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study)

Mario Mandalà, Andrea Ferrari, Ines B. Brecht, Karijn P.M. Suijkerbuijk et autres

BACKGROUND: Data on the efficacy and safety of anti PD-1 antibodies in children and adolescents (CA) with melanoma are lacking. The aim of this study was to determine outcomes of CA melanoma patients receiving anti PD-1 antibodies. METHODS: Melanoma patients ≤18 years …

it, de, nl, au, se, fr, pl, es, tr, il, br (code pays fourni par la source)